Detalhe da pesquisa
1.
Population pharmacokinetics of nintedanib in patients with idiopathic pulmonary fibrosis.
Pulm Pharmacol Ther
; 48: 136-143, 2018 02.
Artigo
Inglês
| MEDLINE | ID: mdl-29133080
2.
Effect of small angiokinase inhibitor nintedanib (BIBF 1120) on QT interval in patients with previously untreated, advanced renal cell cancer in an open-label, phase II study.
Invest New Drugs
; 31(5): 1283-93, 2013 Oct.
Artigo
Inglês
| MEDLINE | ID: mdl-23625328
3.
Clinical Pharmacokinetics and Pharmacodynamics of Nintedanib.
Clin Pharmacokinet
; 58(9): 1131-1147, 2019 09.
Artigo
Inglês
| MEDLINE | ID: mdl-31016670
4.
Population pharmacokinetics of nintedanib, an inhibitor of tyrosine kinases, in patients with non-small cell lung cancer or idiopathic pulmonary fibrosis.
Cancer Chemother Pharmacol
; 81(1): 89-101, 2018 01.
Artigo
Inglês
| MEDLINE | ID: mdl-29119292
5.
Effects of Ketoconazole and Rifampicin on the Pharmacokinetics of Nintedanib in Healthy Subjects.
Eur J Drug Metab Pharmacokinet
; 43(5): 533-541, 2018 Oct.
Artigo
Inglês
| MEDLINE | ID: mdl-29500603
6.
Pharmacokinetics of Nintedanib in Subjects With Hepatic Impairment.
J Clin Pharmacol
; 58(3): 357-363, 2018 03.
Artigo
Inglês
| MEDLINE | ID: mdl-29106740
7.
Pharmacokinetic Properties of Nintedanib in Healthy Volunteers and Patients With Advanced Cancer.
J Clin Pharmacol
; 56(11): 1387-1394, 2016 11.
Artigo
Inglês
| MEDLINE | ID: mdl-27093880
8.
Nintedanib: from discovery to the clinic.
J Med Chem
; 58(3): 1053-63, 2015 Feb 12.
Artigo
Inglês
| MEDLINE | ID: mdl-25474320